(Total Views: 388)
Posted On: 02/11/2021 11:18:05 AM
Post# of 153834
Since Tocilizumab is not part of SoC, and 2094 patients is a pretty sizeable group, let's just stick with the SOC control group and its mortality of just over 33%.
At that rate, 43 of the 87 deaths in CD12 would be in the SOC arm, and 44 in the twice-as-large Leron arm. In other words, very close to a 50% reduction.
That may be too good to be true, but it might also BE true.
At that rate, 43 of the 87 deaths in CD12 would be in the SOC arm, and 44 in the twice-as-large Leron arm. In other words, very close to a 50% reduction.
That may be too good to be true, but it might also BE true.
(11)
(0)
